期刊
MULTIPLE SCLEROSIS AND RELATED DISORDERS
卷 45, 期 -, 页码 -出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.msard.2020.102398
关键词
Multiple sclerosis; Ocrelizumab; Pregnancy; Disease-modifying therapy; B-cells
资金
- Sylvia Lawry Physician Fellowship through the National Multiple Sclerosis Society [FP-1605-08753]
- Institutional Review Board (IRB)
Management of multiple sclerosis (MS) before and during pregnancy remains challenging given there are no disease-modifying therapies (DMTs) approved for use during pregnancy, and discontinuation of certain DMTs can lead to rebound relapses. Ocrelizumab is a highly effective therapy for relapsing-remitting MS (RRMS) without reported rebound after discontinuation. However, little is known about the safety of ocrelizumab before or during pregnancy. We report a case of second trimester ocrelizumab exposure in a patient with RRMS transitioning off natalizumab, that resulted in no neonatal B-cell depletion, no infections, and normal infant development, despite suppressed B-cells in the mother at delivery.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据